Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company based in Philadelphia, focuses on addressing neurodegenerative diseases through innovative therapies. The company has announced its participation in two significant investor conferences, enhancing its visibility in the financial community.

On February 26, 2026, Passage Bio will join the Oppenheimer 36th Annual Healthcare Life Sciences Conference with a presentation scheduled for 8:40 a.m. ET in a virtual format. This will be followed by their participation in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, with a presentation at 1:50 p.m. ET in Boston, MA. Interested investors can access live webcasts of these events through the Investors & Media section of Passage Bio’s website, with replays available for 30 days after each event.

Passage Bio is dedicated to developing advanced genetic therapies aimed at improving the lives of patients afflicted with neurodegenerative disorders. The company's flagship product candidate, PBFT02, is designed to treat frontotemporal dementia by elevating progranulin levels, thereby restoring lysosomal function and potentially halting the disease's progression.

As part of its mission, Passage Bio is committed to safeguarding patients and their families from the debilitating effects of neurodegenerative conditions. For more information about their innovative approaches and developmental progress, stakeholders are encouraged to visit the company's website at passagebio.com.

For media inquiries, Mike Beyer of Sam Brown Inc. Healthcare Communications can be reached at 312-961-2502 or via email. Investors can contact Stuart Henderson at Passage Bio for further details.

Passage Bio, Inc. (NASDAQ: PASG) is poised for increased visibility and engagement within the investment community as it schedules participation in two major investor conferences in late February and early March 2026. This strategic move emphasizes the company's commitment to transparency and communication as it advances its pivotal research in genetic medicines targeting neurodegenerative diseases.

The company's lead product, PBFT02, is designed to address frontotemporal dementia by enhancing progranulin levels, a critical component in restoring lysosomal function. As neurodegenerative diseases garner heightened attention from both the medical community and investors, Passage Bio’s focus on innovative, one-time therapies positions it well within a niche yet vital market.

Investors should keenly observe the presentations scheduled at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26 and the TD Cowen 46th Annual Health Care Conference on March 4. These forums will provide management with an opportunity to communicate their vision, progress, and future pathway for PBFT02, which could potentially influence stock performance.

From a financial perspective, attending these conferences may positively affect investor sentiment, particularly if management effectively conveys the uniqueness of their therapeutic approach and the potential impact of their products. The upcoming webcasts allow investors who are unable to attend live to review critical insights, further enhancing the stock's transparency.

Looking ahead, the competitive landscape in the neurodegenerative space is intense, with several players vying for investor attention. Passage Bio's participation in these conferences signals its ongoing commitment to innovation and investor communication. For current and prospective investors, it presents an opportunity to closely monitor Passage Bio’s advancements while considering the potential for growth, particularly as they move closer to clinical milestones.